Answers are grounded in this paper and cite their sources.
TAVR is a rapidly evolving, minimally invasive first-line treatment for extreme-risk patients with aortic stenosis, with ongoing research expanding its indications to lower-risk populations and other valve pathologies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Eleid et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: